BCL-2 Inhibitors Combined with the HyperCVAD Regimen for Newly Diagnosed T-lymphoblastic Leukemia/lymphoma.

Clinical trial NCT06598722 · RECRUITING

Trial details

NCT number: NCT06598722
Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Lymphoblastic Lymphoma, Adult Lymphoblastic Leukemia, Acute T-cell

Start date: 2024-08-07
Primary completion: 2026-08-07
Enrollment: 206

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.